» Articles » PMID: 35198788

Physicochemical and Biopharmaceutical Aspects Influencing Skin Permeation and Role of SLN and NLC for Skin Drug Delivery

Overview
Journal Heliyon
Specialty Social Sciences
Date 2022 Feb 24
PMID 35198788
Authors
Affiliations
Soon will be listed here.
Abstract

The skin is a complex and multifunctional organ, in which the static versus dynamic balance is responsible for its constant adaptation to variations in the external environment that is continuously exposed. One of the most important functions of the skin is its ability to act as a protective barrier, against the entry of foreign substances and against the excessive loss of endogenous material. Human skin imposes physical, chemical and biological limitations on all types of permeating agents that can cross the epithelial barrier. For a molecule to be passively permeated through the skin, it must have properties, such as dimensions, molecular weight, pKa and hydrophilic-lipophilic gradient, appropriate to the anatomy and physiology of the skin. These requirements have limited the number of commercially available products for dermal and transdermal administration of drugs. To understand the mechanisms involved in the drug permeation process through the skin, the approach should be multidisciplinary in order to overcome biological and pharmacotechnical barriers. The study of the mechanisms involved in the permeation process, and the ways to control it, can make this route of drug administration cease to be a constant promise and become a reality. In this work, we address the physicochemical and biopharmaceutical aspects encountered in the pathway of drugs through the skin, and the potential added value of using solid lipid nanoparticles (SLN) and nanostructured lipid vectors (NLC) to drug permeation/penetration through this route. The technology and architecture for obtaining lipid nanoparticles are described in detail, namely the composition, production methods and the ability to release pharmacologically active substances, as well as the application of these systems in the vectorization of various pharmacologically active substances for dermal and transdermal applications. The characteristics of these systems in terms of dermal application are addressed, such as biocompatibility, occlusion, hydration, emollience and the penetration of pharmacologically active substances. The advantages of using these systems over conventional formulations are described and explored from a pharmaceutical point of view.

Citing Articles

Surfactant-Driven Effects on the Antifungal Activity of Kunth Essential Oil Encapsulated in Lipid-Based Nanosystems.

Gil G, Kakuda L, Tonani L, von Zeska Kress M, Oliveira W ACS Omega. 2025; 10(8):7876-7887.

PMID: 40060779 PMC: 11886426. DOI: 10.1021/acsomega.4c08578.


Evaluation of Preclinical Efficacy of Curcumin-Loaded Bicosome Systems in Amelioration of Oral Mucositis.

Vergara D, Sanhueza C, Mendez S, Bustamante M, Vega B, Acevedo F Pharmaceutics. 2025; 17(2).

PMID: 40006548 PMC: 11860046. DOI: 10.3390/pharmaceutics17020181.


Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models.

Steyn J, Haasbroek-Pheiffer A, Pheiffer W, Weyers M, van Niekerk S, Hamman J Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006008 PMC: 11859300. DOI: 10.3390/ph18020195.


Topical delivery of siRNA to psoriatic skin model using high molecular weight chitosan derivatives: In vitro and in vivo studies.

Martinez Junior A, Ruiz T, Vilamaior P, Tiera V, Taboga S, Tiera M Drug Deliv Transl Res. 2025; .

PMID: 39907973 DOI: 10.1007/s13346-025-01800-4.


Drug Release and Dermal Drug Permeation Studies of Selected Commercial Benzoyl Peroxide Topical Formulations: Correlation Between Human and Porcine Skin Models.

Brighenti M, Montanheri L, Duque M, Andreo-Filho N, Lopes P, Garcia M Mol Pharm. 2025; 22(3):1365-1372.

PMID: 39899465 PMC: 11881039. DOI: 10.1021/acs.molpharmaceut.4c01058.


References
1.
Herwadkar A, Sachdeva V, Taylor L, Silver H, Banga A . Low frequency sonophoresis mediated transdermal and intradermal delivery of ketoprofen. Int J Pharm. 2011; 423(2):289-96. DOI: 10.1016/j.ijpharm.2011.11.041. View

2.
Kolli C, Chadha G, Xiao J, Parsons D, Jayachandra Babu R . Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro. J Drug Target. 2009; 18(9):657-64. DOI: 10.3109/10611860903494237. View

3.
Moser K, Kriwet K, Kalia Y, Guy R . Enhanced skin permeation of a lipophilic drug using supersaturated formulations. J Control Release. 2001; 73(2-3):245-53. DOI: 10.1016/s0168-3659(01)00290-5. View

4.
Lee S, Jeong S, Ahn S . An update of the defensive barrier function of skin. Yonsei Med J. 2006; 47(3):293-306. PMC: 2688147. DOI: 10.3349/ymj.2006.47.3.293. View

5.
Doktorovova S, Souto E, Silva A . Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines. Pharm Dev Technol. 2017; 23(1):96-105. DOI: 10.1080/10837450.2017.1384491. View